Healthcare provider profile · identity verified

Mohammad Sheikhai, MD

Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1972584274

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mohammad Sheikhai, MD received $338.98 in general payments during 2025 across 3 reported records.

Xeris Pharmaceuticals, Inc. accounted for 35.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$338.98

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Xeris Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$121.83	35.9%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$117.63	34.7%	1	2025
Dexcom, Inc.	Unresolved — no canonical attribution shown	$99.52	29.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$338.98	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
GVOKE HYPOPEN Normalized: gvoke hypopen	Drug	Xeris Pharmaceuticals, Inc.	$121.83	1	2025
Source payment records 2025-04-23 · Xeris Pharmaceuticals, Inc. · $121.83 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$117.63	1	2025
Source payment records 2025-05-21 · Novo Nordisk Inc · $117.63 · Open Payments source
Dexcom G6 Transmitter Normalized: dexcom g6 transmitter	Medical Supply	Dexcom, Inc.	$99.52	1	2025
Source payment records 2025-10-22 · Dexcom, Inc. · $99.52 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	102	23
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	639	230
Gabapentin	Gabapentin	409	122
Amlodipine Besylate	Amlodipine Besylate	354	125
Lisinopril	Lisinopril	346	119
Losartan Potassium	Losartan Potassium	331	112
Levothyroxine Sodium	Levothyroxine Sodium	324	102
Omeprazole	Omeprazole	269	90
Tamsulosin Hcl	Tamsulosin Hcl	252	86
Metformin Hcl	Metformin Hcl	229	83
Albuterol Sulfate Hfa	Albuterol Sulfate	223	80
Metoprolol Succinate	Metoprolol Succinate	219	78
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	201	50
Furosemide	Furosemide	196	70
Rosuvastatin Calcium	Rosuvastatin Calcium	187	67
Tramadol Hcl	Tramadol Hcl	183	48
Vitamin D2	Ergocalciferol (Vitamin D2)	171	54
Alprazolam	Alprazolam	162	42
Alendronate Sodium	Alendronate Sodium	158	42
Pantoprazole Sodium	Pantoprazole Sodium	151	53
Buspirone Hcl	Buspirone Hcl	150	54
Trazodone Hcl	Trazodone Hcl	145	39
Eliquis	Apixaban	136	38
Glimepiride	Glimepiride	126	47
Baclofen	Baclofen	122	49
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	120	31
Hydrochlorothiazide	Hydrochlorothiazide	116	41
Fluticasone Propionate	Fluticasone Propionate	115	55
Hydroxyzine Hcl	Hydroxyzine Hcl	112	32
Simvastatin	Simvastatin	112	37
Ibuprofen	Ibuprofen	110	39
Zolpidem Tartrate	Zolpidem Tartrate	105	21
Ozempic	Semaglutide	102	23
Meloxicam	Meloxicam	101	34
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	87	39
Metoprolol Tartrate	Metoprolol Tartrate	85	34
Allopurinol	Allopurinol	83	30
Donepezil Hcl	Donepezil Hcl	81	26
Finasteride	Finasteride	79	26
Carvedilol	Carvedilol	76	27
Tizanidine Hcl	Tizanidine Hcl	75	26
Mirtazapine	Mirtazapine	73	18
Naproxen	Naproxen	73	20
Clopidogrel	Clopidogrel Bisulfate	72	28
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	69	24
Famotidine	Famotidine	68	27
Spironolactone	Spironolactone	68	22
Duloxetine Hcl	Duloxetine Hcl	66	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	65	22
Potassium Chloride	Potassium Chloride	64	23
Meclizine Hcl	Meclizine Hcl	62	27
Prednisone	Prednisone	62	32
Citalopram Hbr	Citalopram Hydrobromide	61	17
Ropinirole Hcl	Ropinirole Hcl	61	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	59	44
Glipizide	Glipizide	59	19
Montelukast Sodium	Montelukast Sodium	59	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	21
Metformin Hcl Er	Metformin Hcl	54	22
Azithromycin	Azithromycin	53	40
Pioglitazone Hcl	Pioglitazone Hcl	53	17
Pravastatin Sodium	Pravastatin Sodium	53	17
Atenolol	Atenolol	51	18
Levetiracetam	Levetiracetam	51	13
Warfarin Sodium	Warfarin Sodium	45	14
Quetiapine Fumarate	Quetiapine Fumarate	44	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	44	28
Acetaminophen-Codeine	Acetaminophen With Codeine	43	23
Glipizide Er	Glipizide	42	15
Xarelto	Rivaroxaban	41	suppressed
Celecoxib	Celecoxib	40	15
Fenofibrate	Fenofibrate	39	suppressed
Hydralazine Hcl	Hydralazine Hcl	39	14
Temazepam	Temazepam	39	suppressed
Nifedipine Er	Nifedipine	38	11
Torsemide	Torsemide	38	12
Oxybutynin Chloride	Oxybutynin Chloride	37	13
Ezetimibe	Ezetimibe	36	14
Nystatin	Nystatin	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	35	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	35	12
Humalog Kwikpen U-100	Insulin Lispro	34	17
Sertraline Hcl	Sertraline Hcl	34	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	33	13
Oxybutynin Chloride Er	Oxybutynin Chloride	33	13
Terbinafine Hcl	Terbinafine Hcl	33	11
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	32	11
Jardiance	Empagliflozin	32	11
Levofloxacin	Levofloxacin	32	26
Lidocaine	Lidocaine	32	15
Doxycycline Monohydrate	Doxycycline Monohydrate	31	13
Mounjaro	Tirzepatide	31	suppressed
Terazosin Hcl	Terazosin Hcl	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Acyclovir	Acyclovir	30	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Rybelsus	Semaglutide	30	suppressed
Testosterone Cypionate	Testosterone Cypionate	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	14
Lorazepam	Lorazepam	29	suppressed
Methocarbamol	Methocarbamol	29	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	29	13
Methylprednisolone	Methylprednisolone	28	20
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	22
Ondansetron Odt	Ondansetron	27	11
Sildenafil Citrate	Sildenafil Citrate	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	22
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	25	suppressed
Fluconazole	Fluconazole	25	21
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	24	suppressed
Hydrocortisone	Hydrocortisone	24	14
Amoxicillin	Amoxicillin	23	17
Diazepam	Diazepam	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Myrbetriq	Mirabegron	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	11
Minoxidil	Minoxidil	22	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Lactulose	Lactulose	20	suppressed
Mometasone Furoate	Mometasone Furoate	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Piroxicam	Piroxicam	19	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	18	11
Cyproheptadine Hcl	Cyproheptadine Hcl	17	11
Repaglinide	Repaglinide	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Methadone Hcl	Methadone Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Indomethacin	Indomethacin	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Primidone	Primidone	14	suppressed
Risperidone	Risperidone	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Topiramate	Topiramate	14	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	13	suppressed
Lacosamide	Lacosamide	13	suppressed
Methimazole	Methimazole	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Desipramine Hcl	Desipramine Hcl	11	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Megestrol Acetate	Megestrol Acetate	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$338.98 · 3 records	Xeris Pharmaceuticals, Inc.	Dexcom G6 Transmitter, GVOKE HYPOPEN, Wegovy	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error